ADC Therapeutics S.A. (ADCT) Stock

ADC Therapeutics S.A. (ADCT) is a Healthcare stock trading at $1.08 (as of 2026-06-18), with a market capitalization of $391.75M and a trailing P/E of -1.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ADC Therapeutics S.A. develops antibody-drug conjugates for patients with hematologic cancers and solid tumors. Its pipeline includes ZYNLONTA and camidanlumab tesirine, plus candidates such as ADCT-602, ADCT-601 and ADCT-901, each in clinical development for indications including non-Hodgkin and Hodgkin lymphomas, acute lymphoblastic leukemia and selected solid tumors.

Valuation — source: SEC EDGAR (first-party)
Price	$1.08
Market Cap	$391.75M
P/E Ratio	-1.1
EV / EBITDA	0.8
Price / Book	-0.62
Price / Sales	1.69
DCF Value (model)	$-16.92
DCF Upside vs Price	-1666.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$81.36M
Net Margin	-175.3%
Return on Equity	63.3%
Debt / Equity	-0.02
Current Ratio	4.09
Revenue Growth (YoY)	-9.5%
EPS Growth (YoY)	-41.7%
FCF Growth (YoY)	-47.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-7.04 (distress)
Piotroski F-Score	5/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-1.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-105.2%
vs Industry	-106.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Redmile Group, LLC ($58.01M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ameet Mallik
Employees	263
Country	CH
IPO Date	2020-05-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.